-
Renfu Medicine HW021199 tablets are approved for clinical use in the treatment of idiopathic pulmonary fibrosis
Time of Update: 2021-07-07
On April 30, Renfu Medicine issued an announcement stating that recently, its subsidiary Hubei Biomedical Industry Technology Research Institute Co.
(referred to as the "Research Institute Co.
Only two drugs, nintedanib and pirfenidone, are approved for the treatment of idiopathic pulmonary fibrosis .
-
An enterprise in Jilin Province was reported and fined 113,000
Time of Update: 2021-07-07
The Food and Drug Administration finally imposed the following penalties on the company: Confiscated 77,800 medical surgical masks that did not meet the requirements of mandatory industry standards; fined 5 times the value of the goods totaling RMB 113,850 .
-
With a monthly salary of 31 yuan to a net worth of 5 billion, how can he increase the profit of "genetic engineering drugs" by 600%?
Time of Update: 2021-07-07
"Anke Biology: Two brothers started a company and now they have a net worth of 1 billion yuan" - https:// 2.
"Anke Biology: Song Lihua's First Pot of Gold" - http://news.
-
One week of strong sugar control and full "heart" benefit, smegaglutide injection Novotai® was approved in China
Time of Update: 2021-07-07
As a heavy week of GLP-1 administered products, Novo Thai ® to breakthrough technology will extend the half-life of up to 7 days to achieve administered once a week potent sugar control, precise standards, and benefit from a comprehensive cardiometabolic , To provide more effective, simple and safe treatment options for Chinese patients with type 2 diabetes .
-
The third domestic Boan Bio-bevacizumab injection (Boyounuo) was approved for listing in China
Time of Update: 2021-07-07
Luye Pharmaceutical Group announced that the bevacizumab injection (Boyounuo®) developed by its holding subsidiary Boan Biotechnology has been officially approved by the China National Medical Products Administration for the treatment of advanced, metastatic or recurrent non- Small cell lung cancer and metastatic colorectal cancer .
-
Shanggao Company Announces Appointment of New CEO
Time of Update: 2021-07-07
Yang has served as a partner of Wuhan Sinopharm Optics Valley Capital Management Co.
Yang Ou to join us as CEO at an important juncture in the transformation of Shanggao ’s main industries.
-
Zhongchao Medical releases financial results for fiscal year 2020
Time of Update: 2021-07-07
Zhongchao Medical (NASDAQ transaction code: ZCMD) (referred to as "Zhongchao Medical" or "Company"), a company dedicated to providing online healthcare information, professional medical training and education services for Chinese medical workers and the general public, in Today announced its financial results for the fiscal year ending December 31, 2020 .
-
Interventional vascular therapy "Shuangjie", Huashan Hospital applies therapy to promote the development of intracranial aneurysm treatment
Time of Update: 2021-07-07
Professor Gu Yuxiang introduced to us: "Since the 1990s, spring embolization therapy in interventional endovascular treatment has gradually emerged, providing patients with minimally invasive and safe surgical options.
-
Dejin Medical completed hundreds of millions of dollars in Series B investment, led by Dehong Capital and Sequoia China
Time of Update: 2021-07-07
The financing amounted to hundreds of millions of dollars, and the funds will be mainly used for the company's technological innovation and product development in the treatment of mitral and tricuspid valve diseases .
-
Yuyue Medical hires Zhang Yong as deputy general manager and chief financial officer
Time of Update: 2021-07-07
Zhang Yong as the company's deputy general manager , Chief Financial Officer, responsible for the company's digital operations and financial management, and his term of office will end until the expiration of the current board of directors .
-
Mengdi sells China business for $1 billion?
Time of Update: 2021-07-07
The following is our inventory of the main events in the sales, sales, and sanctions of multinational pharmaceutical companies in China in the past two years: In March 2021, Eli Lilly’s business model will be adjusted In March 2021, Eli Lilly China announced its decision to deal with the sales and regional marketing team of Engligliflozin (Chinese product name: Ou Tangjing), as well as the hybrid sales team of Xinbaida, Cialli, and Futaiao (ie CCO).
-
National TCM Peritoneal Dialysis Alliance Dialysis New Technology Seminar launched
Time of Update: 2021-07-07
Traditional Chinese medicine has unique advantages in improving peritoneal dialysis and the quality of life of patients, and has achieved remarkable results in recent years .
-
Two asset reorganizations, transformation of CRO business, Baihua Village still cannot escape the predicament
Time of Update: 2021-07-07
However, compared with typical CXO companies such as Zhaoyan New Medicine and Yaoshi Technology with revenues of more than 1 billion yuan, a company that was once known as the "dark horse of the CRO sector" not only had revenue of less than 100 million last year, but also suffered a substantial loss in net profit.
-
Oculis, an ophthalmic biopharmaceutical company, has over-completed Series C financing, and Baiao Wealth and Huiding Investment jointly led the investment
Time of Update: 2021-07-07
This round of financing was jointly led by Baiao Wealth and Huiding Investment, both of which invested in Oculis for the first time; existing shareholders VI Partners and Wille AG also participated in the investment .
-
Luoxin Pharmaceutical's revenue in the first quarter increased by 36.62%, and the full-year performance in the post-epidemic era can be expected
Time of Update: 2021-07-07
From realizing the replacement of original research with high quality and high price to the initiative to solve unmet clinical needs, Luoxin Pharmaceuticals not only continues to improve R&D and innovation capabilities and industrialization capabilities, but also pays more attention to drugs with clinical advantages in the world, relying on strong Clinical advancement capabilities, Chinese market channel advantages and strong commercialization capabilities have accelerated the development and listing of drugs in China .
-
Rongchang Biological announced its plan to go public on the Science and Technology Innovation Board!
Time of Update: 2021-07-07
Subsequently, soon after its listing on the Hong Kong Stock Exchange in November 2020, Rongchang Biotech ushered in the first innovative drug approved for marketing in March this year-the "dual target" new drug for systemic lupus erythematosus, tytacept .
-
The real "water droplets" in the prospectus: the termination of the mutual aid plan has no impact and the race for the trillion-dollar health track
Time of Update: 2021-07-07
Waterdrop Company disclosed in the prospectus that the first-year premium (FYP) of Waterdrop Insurance mainly comes from four aspects, namely, Waterdrop Mutual Assistance, Waterdrop Chip, third-party traffic channels, and organic traffic and repurchase .
-
WuXi Biologics announces the completion of three acquisitions including Pfizer's original solution preparation production base
Time of Update: 2021-07-07
WuXi Biologics announced today that it has completed three acquisitions of Bayer's original solution production base in Wuppertal, Germany, Pfizer China's original solution and preparation production base in Hangzhou, and China's contracted biological drug development and production company (CDMO) Suqiao Biologics .
-
Innovation and refined operations, Meinian Health’s first-quarter revenue of 1.332 billion
Time of Update: 2021-07-07
It is understood that Meinian Health not only provides professional physical examination services, but also makes technological innovations in disease diagnosis screening and artificial intelligence-assisted diagnosis with its advantages in scale, management and operation, and data accumulation .
-
Winbond Health Methylprednisolone Sodium Succinate for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-07-06
On June 9th, Winbond Health announced that Winbond Pharmaceuticals, a wholly-owned subsidiary, has recently received the "Notice of Supplementary Application Approval" for methylprednisolone sodium succinate for chemical injections approved and issued by the National Medical Products Administration.
